tiprankstipranks
Shield Therapeutics PLC (GB:STX)
LSE:STX
Holding GB:STX?
Track your performance easily

Shield Therapeutics (STX) Income Statement

18 Followers

Shield Therapeutics Income Statement

Last quarter (Q4 2021), Shield Therapeutics's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Shield Therapeutics's net income was £―. See Shield Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-£ 13.32M£ 5.60M£ 1.52M£ 10.39M£ 719.00K
Cost of Revenue
-£ 9.06M£ 3.04M£ 980.00K£ 1.35M£ 485.00K
Gross Profit
-£ 4.26M£ 2.56M£ 539.00K£ 9.03M£ 234.00K
Operating Expense
-£ 37.46M£ 35.55M£ 20.49M£ 11.19M£ 9.27M
Operating Income
-£ -33.20M£ -32.99M£ -19.95M£ -2.15M£ -9.04M
Net Non Operating Interest Income Expense
-£ -1.04M£ -442.00K£ -5.00K£ -2.00K£ -16.00K
Other Income Expense
-£ -1.87M£ -1.35M---
Pretax Income
-£ -32.38M£ -49.34M£ -19.57M£ -1.89M£ -9.07M
Tax Provision
-£ 918.00K£ 446.00K£ -229.00K£ 744.00K£ -266.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -33.29M£ -49.79M£ -19.34M£ -2.63M£ -8.80M
Basic EPS
-£ -0.05£ -0.21£ -0.09£ -0.02£ -0.08
Diluted EPS
-£ -0.05£ -0.21£ -0.09£ -0.02£ -0.08
Basic Average Shares
-£ 722.54M£ 233.19M£ 204.02M£ 117.23M£ 116.99M
Diluted Average Shares
-£ 722.54M£ 233.19M£ 204.02M£ 117.23M£ 116.99M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-£ 46.52M£ 38.59M£ -21.47M£ -12.54M£ -9.75M
Net Income From Continuing And Discontinued Operation
-£ -33.29M£ -49.79M£ -19.34M£ -2.63M£ -8.80M
Normalized Income
-£ -24.28M£ -21.86M£ -19.79M£ -1.53M£ -9.33M
Interest Expense
------
EBIT
-£ -30.81M£ -48.86M£ -19.57M£ -1.89M£ -9.06M
EBITDA
-£ -29.74M£ -46.20M£ -19.57M£ 819.00K£ -9.06M
Currency in GBP

Shield Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis